This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering



WMT develops treatments for cancer and chronic inflammatory conditions using a novel principle: Induction of the ER/ISR stress response through potent small molecules! Our ER/ISR stress induces hit preferentially rapidly dividing and metabolically very active cells, i.e. cancer cells and highly activated immune cells. For cancer applications we have elected a clinical candidate, B-306, where we can demonstrate efficacy in various animal models, syngeneic and xenograft, up to 28 days. We plan for IND filing for a first Phase I study in solid cancers (targets are ovarian, urothelial, renal, pancreas and liver) within 15 months upon availabilizty of funding. We seek for venture or private funding to raise 10M Euros+ for entry into clinical development.